Teva Pharmaceutical

Investor's Business Daily

Teva Pharmaceutical (TEVA), the Israeli drugmaker, said EPS rose 2% to $1.28, beating estimates by 3 cents. Revenue rose 15% to $4.97 bil, below outlook for $5.07 bil. Teva forecast '12 EPS of $5.32-$5.38, a penny below views. Teva shares rose 2.2% to 41.31.

View Comments (0)